



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/171,607	11/04/1998	WOLF-GEORG FORSSMANN	P63132USO	8253

7590

06/04/2002

JACOBSON PRICE HOLMAN & STERN  
400 SEVENTH STREET NW  
WASHINGTON, DC 20004

EXAMINER

DECLoux, AMY M

ART UNIT

PAPER NUMBER

1644

DATE MAILED: 06/04/2002

18

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES  
PATENT AND TRADEMARK OFFICE  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/171,607	10/09/01	Forssmann	P63132USO

EXAMINER	
Amy DeCloux	
ART UNIT	PAPER NUMBER
1644	18

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

Applicant's amendments filed 1-9-02 and 3-19-02 (Papers No. 16 and 17, respectively) are acknowledged and have been entered. It is noted that newly added claim 63 recites fragments of the peptide according to claim 43 having pharmacological activity in humans. However in the remarks section of the amendment filed 1-9-02, applicants state they have limited the claims to the peptide of SEQ ID NO:1 and some derivatives, and therefore submit that the 112 first paragraph rejection over derivatives and fragments is overcome. However this statement is a contradiction in view of Applicant's newly added claim 63. Therefore, it is not clear if applicant intends to claim fragments. Clarification is required.

Since the above-mentioned reply appears to be *bona fide*, applicant is given a TIME PERIOD of ONE EXTENDABLE MONTH, from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME LIMIT MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Amy DeCloux, Art Unit 1644, whose telephone number is (703) 306-5821.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Amy DeCloux, Ph.D.  
Patent Examiner  
Art Unit 1644  
June 3, 2002

*Amy DeCloux*  
6-3-02